RELMADA THERAPEUTICS, INC. Annual Operating Income (Loss) in USD from 2012 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Relmada Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2012 to 2023.
  • Relmada Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$23M, a 1.39% decline year-over-year.
  • Relmada Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$91.6M, a 20.7% increase year-over-year.
  • Relmada Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$104M, a 35.7% increase from 2022.
  • Relmada Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$161M, a 28.3% decline from 2021.
  • Relmada Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$126M, a 107% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$104M +$57.5M +35.7% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-19
2022 -$161M -$35.5M -28.3% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-19
2021 -$126M -$64.9M -107% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-23
2020 -$60.8M -$45.7M -303% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-25
2019 -$15.1M -$8.19M -118% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-24
2018 -$6.92M +$301K +4.18% Jul 1, 2017 Jun 30, 2018 10-KT 2020-03-26
2017 -$7.22M +$9M +55.5% Jul 1, 2016 Jun 30, 2017 10-K 2018-09-28
2016 -$16.2M +$884K +5.17% Jul 1, 2015 Jun 30, 2016 10-K 2017-09-28
2015 -$17.1M Jul 1, 2014 Jun 30, 2015 10-K 2016-09-09
2013 -$6.77M -$3.62M -115% Jan 1, 2013 Dec 31, 2013 10-K 2015-09-11
2012 -$3.16M Jan 1, 2012 Dec 31, 2012 10-KT 2014-09-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.